 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Sera Prognostics' 4,000-Patient Validation Study Another Sign of High-Throughput Mass Spec's Arrival
March 01, 2013
Sera Prognostics' 4,000-Patient Validation Study Another Sign of High-Throughput Mass Spec's Arrival
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- New Vendor Collaborations, Publications, Products Suggest Clinical Mass Spec 'Ready for Prime Time'
February 15, 2013 / ProteoMonitor - Big Names Join Clinical Proteomics Push in 2011, Offering Ray of Optimism Amidst Difficult Year
January 6, 2012 / ProteoMonitor - Caprion Leading $21M Clinical Biomarker and Personalized Medicine Development Project
February 22, 2013 / ProteoMonitor - Targeted Mass Spec Slowly but Steadily Moving Toward Broader Commercial, Clinical Adoption
September 21, 2012 / ProteoMonitor - Eyeing 2013 Launch of Mass Spec Preterm Birth Test, Sera Closes $19.3M Round, Names Critchfield CEO
November 18, 2011 / ProteoMonitor